Shane G. Supple

All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

Harry Iland, Ken Bradstock, Shane G. Supple et al. · Blood · 2012 · 336 citations · Full text

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

Michael C. Heinrich, Heikki Joensuu, George D. Demetri et al. · Clinical Cancer Research · 2008 · 212 citations

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial

Harry Iland, Marnie Collins, Ken Bradstock et al. · The Lancet Haematology · 2015 · 165 citations

Hematological Malignancy, Oncology, Malignant Blood Disorder +8

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia

Harry Iland, K. F. Bradstock, John F. Seymour et al. · Haematologica · 2011 · 59 citations · Full text

A spontaneous novel XK gene mutation in a patient with McLeod syndrome

Shane G. Supple, Harry Iland, Michael Barnett et al. · British Journal of Haematology · 2001 · 17 citations · Full text